Novocure has filed an application asking the U.S. Food and Drug Administration to approve its Tumor Treating Fields (TTFields) therapy for treating locally advanced…
News
A combination therapy for glioblastoma showed encouraging early results, with all five patients treated in a pilot study responding to it. Based on the data,…
GYNECOLOGICAL CANCER
Stenoparib wins FDA fast track status for advanced ovarian cancer
The U.S. Food and Drug Administration (FDA) has given fast track status to stenoparib, an experimental treatment Allarity Therapeutics has been testing for advanced…
The first patient has been dosed in a Phase 1 clinical trial that’s testing a gene therapy for people with recurring or treatment-resistant multiple…
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral therapy XS003 (nilotinib) for the…
PANCREATIC CANCER
Study provides insight into pancreatic cancer development
Glitches in a cellular process that are often seen in neurodegenerative diseases and dementia may also play a role in pancreatic cancer development, a…
Jazz Pharmaceuticals said the U.S. Food and Drug Administration (FDA) granted accelerated approval to the weekly oral therapy dordaviprone, to be marketed under the brand…
GYNECOLOGICAL CANCER
‘Off-the-shelf’ NKT cell therapy can overcome ovarian cancer defenses
A cell-based immunotherapy that’s designed to overcome the defense mechanisms that help ovarian cancer evade treatment was highly effective at killing cancer cells in preclinical…
The European Union (EU) expanded its approval of Sarclisa (isatuximab-irfc), making it available to newly diagnosed adults with multiple myeloma who are eligible for…
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment